Marcel N Moyeh
Overview
Explore the profile of Marcel N Moyeh including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
10
Citations
84
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Tangi L, Ajonina M, Moyeh M, Chi H, Ntui V, Kwi P, et al.
Front Public Health
. 2023 May;
11:1060479.
PMID: 37181692
Background: Despite a scale up of control interventions over the years, malaria remains a major public health and economic concern in Cameroon, contributing considerably to hospitalization and deaths. The effectiveness...
2.
Mbacham H, Mosume D, Apinjoh T, Ntui V, Moyeh M, Kalaji L, et al.
Malar J
. 2023 Mar;
22(1):73.
PMID: 36864514
Background: Plasmodium falciparum resistance to intermittent preventive treatment with sulfadoxine-pyrimethamine (IPTp-SP) continues to spread throughout sub-Saharan Africa. This study assessed the occurrence of microscopic and sub-microscopic P. falciparum parasitaemia, dihydropteroate...
3.
Apinjoh T, Ntui V, Chi H, Moyeh M, Toussi C, Mayaba J, et al.
PLoS One
. 2022 Sep;
17(9):e0275370.
PMID: 36178962
The current guidelines for malaria prevention and control during pregnancy in Africa is predicated on the prevention of infection and/or disease through intermittent preventive treatment in pregnancy (IPTp), insecticide-treated nets...
4.
Kwi P, Ewane E, Moyeh M, Tangi L, Ntui V, Zeukeng F, et al.
Parasit Vectors
. 2022 Sep;
15(1):344.
PMID: 36171589
Background: Malaria remains endemic in Cameroon, with heterogeneous transmission related to eco-climatic variations, vector diversity and spatial distribution. The intensification of malaria prevention and control through the free distribution of...
5.
Eyong E, Etutu S, Jerome F, Nyasa R, Kwenti T, Moyeh M
IJID Reg
. 2022 Jun;
3:300-307.
PMID: 35755467
Objective: produces histidine-rich protein 2/3 () genes that accumulate to high levels in the bloodstream and serve as a diagnostic and prognostic marker for malaria. gene deletions may lead to...
6.
Niba P, Nji A, Ali I, Akam L, Dongmo C, Chedjou J, et al.
BMC Infect Dis
. 2022 Feb;
22(1):166.
PMID: 35189818
Background: Many studies have reported high efficacy and safety of artesunate-amodiaquine (AS-AQ) and artemether-lumefantrine (AL) when administered under direct observation in Cameroon. There is paucity of data to support their...
7.
Niba P, Nji A, Evehe M, Ali I, Netongo P, Ngwafor R, et al.
Malar J
. 2021 Jan;
20(1):32.
PMID: 33422080
Background: Malaria remains highly endemic in Cameroon. The rapid emergence and spread of drug resistance was responsible for the change from monotherapies to artemisinin-based combinations. This systematic review and meta-analysis...
8.
Moyeh M, Ali I, Njimoh D, Nji A, Netongo P, Evehe M, et al.
J Parasitol Res
. 2019 Apr;
2019:1417967.
PMID: 30984417
Background: Despite recommendation from the World Health Organization that all malaria suspected patients undergo a parasitological confirmation using rapid diagnostic test or light microscopy prior to treatment, health facilities in...
9.
Moyeh M, Njimoh D, Evehe M, Ali I, Nji A, Nkafu D, et al.
Malar Res Treat
. 2018 Jun;
2018:7071383.
PMID: 29854394
Background: As a result of the spread of parasites resistant to antimalarial drugs, Malaria treatment guidelines in Cameroon evolved from nonartemisinin monotherapy to artemisinin-based combination therapy. The aim of this...
10.
Nji A, Ali I, Moyeh M, Ngongang E, Ekollo A, Chedjou J, et al.
Malar J
. 2015 Jan;
14:27.
PMID: 25626448
Background: Artemether-lumefantrine and artesunate-amodiaquine are first-line treatment for uncomplicated malaria in Cameroon. No study has yet compared the efficacy of these drugs following the WHO recommended 42-day follow-up period. The...